 Diana Abbott
Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 7 | 2026 | 686 | 0.720 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 7 | 2026 | 280 | 0.690 |
Why?
| | Plants, Edible | 1 | 2019 | 9 | 0.590 |
Why?
| | Harm Reduction | 1 | 2019 | 50 | 0.550 |
Why?
| | Sulfonamides | 7 | 2026 | 581 | 0.520 |
Why?
| | Marijuana Smoking | 1 | 2019 | 249 | 0.450 |
Why?
| | Cannabis | 2 | 2019 | 509 | 0.440 |
Why?
| | Wounds, Gunshot | 1 | 2019 | 258 | 0.440 |
Why?
| | Azacitidine | 4 | 2026 | 157 | 0.380 |
Why?
| | Emergency Service, Hospital | 3 | 2019 | 2379 | 0.370 |
Why?
| | Cord Blood Stem Cell Transplantation | 2 | 2024 | 103 | 0.360 |
Why?
| | Firearms | 1 | 2019 | 437 | 0.360 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2024 | 700 | 0.340 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2026 | 1965 | 0.310 |
Why?
| | Graft vs Host Disease | 3 | 2024 | 281 | 0.300 |
Why?
| | Laryngeal Neoplasms | 2 | 2017 | 36 | 0.250 |
Why?
| | Transplantation Conditioning | 2 | 2024 | 191 | 0.220 |
Why?
| | Transplantation, Haploidentical | 1 | 2024 | 23 | 0.210 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2024 | 193 | 0.180 |
Why?
| | Multiple Myeloma | 1 | 2023 | 309 | 0.150 |
Why?
| | Psychoses, Substance-Induced | 1 | 2019 | 16 | 0.150 |
Why?
| | Lymphoma, Follicular | 1 | 2019 | 56 | 0.150 |
Why?
| | Directive Counseling | 1 | 2019 | 44 | 0.140 |
Why?
| | Cytochrome P-450 CYP2D6 Inhibitors | 1 | 2018 | 4 | 0.140 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2019 | 117 | 0.140 |
Why?
| | Dextromethorphan | 1 | 2018 | 24 | 0.140 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2018 | 32 | 0.140 |
Why?
| | Pharmacogenomic Variants | 1 | 2018 | 33 | 0.140 |
Why?
| | Retrospective Studies | 9 | 2024 | 17269 | 0.140 |
Why?
| | Vomiting | 1 | 2019 | 132 | 0.140 |
Why?
| | Neoplastic Stem Cells | 2 | 2020 | 409 | 0.140 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2017 | 56 | 0.130 |
Why?
| | Marijuana Abuse | 1 | 2019 | 211 | 0.120 |
Why?
| | Remission Induction | 3 | 2026 | 309 | 0.120 |
Why?
| | Antineoplastic Agents | 2 | 2026 | 2207 | 0.120 |
Why?
| | Acute Disease | 1 | 2019 | 1040 | 0.120 |
Why?
| | Hodgkin Disease | 1 | 2017 | 171 | 0.110 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2017 | 264 | 0.110 |
Why?
| | Middle Aged | 10 | 2026 | 36176 | 0.110 |
Why?
| | Colorado | 3 | 2019 | 4572 | 0.110 |
Why?
| | Antibodies, Monoclonal | 2 | 2023 | 1511 | 0.110 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2020 | 881 | 0.100 |
Why?
| | Humans | 20 | 2026 | 145491 | 0.100 |
Why?
| | Aged | 10 | 2026 | 26125 | 0.090 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2017 | 644 | 0.090 |
Why?
| | Male | 12 | 2026 | 72817 | 0.090 |
Why?
| | Neutrophils | 1 | 2017 | 1124 | 0.090 |
Why?
| | Female | 12 | 2026 | 78763 | 0.080 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2017 | 994 | 0.080 |
Why?
| | Physicians | 1 | 2019 | 952 | 0.080 |
Why?
| | Prognosis | 3 | 2024 | 4323 | 0.070 |
Why?
| | Aged, 80 and over | 4 | 2024 | 8326 | 0.070 |
Why?
| | Treatment Outcome | 4 | 2026 | 11831 | 0.060 |
Why?
| | Adult | 5 | 2024 | 40707 | 0.060 |
Why?
| | Cardiovascular Diseases | 1 | 2019 | 2185 | 0.060 |
Why?
| | Stem Cells | 2 | 2020 | 626 | 0.060 |
Why?
| | Socioeconomic Factors | 2 | 2022 | 1327 | 0.060 |
Why?
| | Kaplan-Meier Estimate | 2 | 2017 | 974 | 0.050 |
Why?
| | Etoposide | 1 | 2024 | 168 | 0.050 |
Why?
| | Vincristine | 1 | 2024 | 140 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2024 | 266 | 0.050 |
Why?
| | Survival Analysis | 2 | 2017 | 1374 | 0.050 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2023 | 42 | 0.050 |
Why?
| | Prednisone | 1 | 2024 | 221 | 0.050 |
Why?
| | Rituximab | 1 | 2024 | 211 | 0.050 |
Why?
| | Doxorubicin | 1 | 2024 | 398 | 0.040 |
Why?
| | Time-to-Treatment | 1 | 2024 | 250 | 0.040 |
Why?
| | ABO Blood-Group System | 1 | 2022 | 57 | 0.040 |
Why?
| | Young Adult | 3 | 2024 | 14192 | 0.040 |
Why?
| | Siblings | 1 | 2022 | 195 | 0.040 |
Why?
| | Allografts | 1 | 2021 | 153 | 0.040 |
Why?
| | Fetal Blood | 1 | 2022 | 325 | 0.040 |
Why?
| | Niacinamide | 1 | 2020 | 87 | 0.040 |
Why?
| | Tricarboxylic Acids | 1 | 2018 | 11 | 0.040 |
Why?
| | Neoplasm, Residual | 1 | 2019 | 143 | 0.040 |
Why?
| | Ketoglutaric Acids | 1 | 2018 | 23 | 0.040 |
Why?
| | Medical Records | 1 | 2019 | 192 | 0.040 |
Why?
| | Electron Transport Complex II | 1 | 2018 | 28 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2019 | 311 | 0.030 |
Why?
| | Succinate Dehydrogenase | 1 | 2018 | 66 | 0.030 |
Why?
| | Substrate Specificity | 1 | 2018 | 396 | 0.030 |
Why?
| | Oxidative Phosphorylation | 1 | 2018 | 209 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2018 | 238 | 0.030 |
Why?
| | Fatty Acids | 1 | 2020 | 459 | 0.030 |
Why?
| | Lymphocyte Count | 1 | 2017 | 165 | 0.030 |
Why?
| | Glottis | 1 | 2017 | 20 | 0.030 |
Why?
| | Drug Interactions | 1 | 2018 | 404 | 0.030 |
Why?
| | Amino Acids | 1 | 2020 | 521 | 0.030 |
Why?
| | Genetic Testing | 1 | 2019 | 480 | 0.030 |
Why?
| | Salvage Therapy | 1 | 2017 | 165 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2017 | 420 | 0.030 |
Why?
| | Administration, Oral | 1 | 2018 | 863 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2017 | 771 | 0.030 |
Why?
| | Lymphocytes | 1 | 2017 | 379 | 0.030 |
Why?
| | Incidence | 1 | 2022 | 2915 | 0.030 |
Why?
| | Insurance Coverage | 1 | 2017 | 243 | 0.030 |
Why?
| | Propensity Score | 1 | 2017 | 376 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2019 | 775 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1544 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1332 | 0.020 |
Why?
| | Genotype | 1 | 2018 | 1853 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2017 | 1468 | 0.020 |
Why?
| | Energy Metabolism | 1 | 2018 | 932 | 0.020 |
Why?
| | Gene Expression | 1 | 2017 | 1478 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 2130 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2019 | 2045 | 0.020 |
Why?
| | Databases, Factual | 1 | 2017 | 1500 | 0.020 |
Why?
| | Models, Biological | 1 | 2018 | 1815 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2017 | 1150 | 0.020 |
Why?
| | Apoptosis | 1 | 2018 | 2411 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 5426 | 0.020 |
Why?
| | Phenotype | 1 | 2018 | 3157 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 3195 | 0.020 |
Why?
| | Cohort Studies | 1 | 2019 | 5992 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 3759 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2017 | 1101 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 6070 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 7171 | 0.010 |
Why?
| | Prospective Studies | 1 | 2018 | 8039 | 0.010 |
Why?
| | Adolescent | 1 | 2024 | 22485 | 0.010 |
Why?
| | Child | 1 | 2024 | 22680 | 0.010 |
Why?
| | United States | 1 | 2017 | 16115 | 0.010 |
Why?
|
|
Abbott's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|